ACTRN12616001422415已完成4 期
Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum in Dolisie, Republic of Congo
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 176
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 6 Months 至 11 Years（—）
- 性别
- All
入选标准
- •1.age between 6 months and 11 years.
- •2.mono-infection with P. falciparum detected by microscopy;
- •3.parasitaemia of 1000–200000/microliter asexual forms;
- •4.presence of axillary temperature equal to or greater than 37.5 degrees centigrade or history of fever during the past 24 h;
- •5.ability to swallow oral medication;
- •6.ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- •7.informed consent from the parent of children
排除标准
- •1.presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);
- •2.weight under 5 kg;
- •3.mixed or mono-infection with another Plasmodium species detected by microscopy;
- •4.presence of severe malnutrition defined as a child aged 6-60 months who has a mid-upper arm circumference < 115 mm;
- •5.presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- •6.regular medication, which may interfere with antimalarial pharmacokinetics;
- •7.history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
研究者
相似试验
尚未招募
4 期
Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Ouesso,MalariaPACTR201905606150545Health Ministry of Congo176
已完成
不适用
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria, and chloroquine for P.vivax in Kyaing Tone (Eastern Shan State)Infection - Other infectious diseasesmalariaACTRN12610000881033Clinical Research Unit (Malaria), Ministry of Defense160
已完成
不适用
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria, and chloroquine for P.vivax in Budethaung (Rakhine), Thanphyuzayat (Mon State), and Kawthaung (Tanintharyi Division)Infection - Other infectious diseasesMalariaACTRN12610000882022Department of Medical Research (Lower Myanmar)160
尚未招募
4 期
Efficacy and safety of artemether-lumefantrine and artesunate-mefloquine for the treatment of uncomplicated falciparum malaria, and chloroquine for vivax malaria in Mu-se Township, Northern Shan State and Kalay-Ta-mu townships, Sagaing Region, MyanmarInfection - Studies of infection and infectious agentsMalariaACTRN12611001245987Department of Medical Research (Upper Myanmar)480
已完成
不适用
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria, and chloroquine for P.vivax in Myit Kyi Nar Township, Kachin State, MyanmarmalariaACTRN12610000880044Department of Medical Research (Upper Myanmar), Ministry of Health240